NASDAQ:ATRS - Nasdaq - US0366421065 - Common Stock
Taking everything into account, ATRS scores 3 out of 10 in our fundamental rating. ATRS was compared to 194 industry peers in the Pharmaceuticals industry. While ATRS seems to be doing ok healthwise, there are quite some concerns on its profitability. ATRS is valued quite expensively, but it does show have an excellent growth rating.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Altman-Z | 8.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.59
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 20.7 | ||
Fwd PE | 68.5 | ||
P/S | 5.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.43 | ||
P/tB | N/A | ||
EV/EBITDA | 29.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 17.97% | ||
ROE | 26.33% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 14.87% | ||
PM (TTM) | 25.15% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.1 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.96 | ||
Quick Ratio | 2.76 | ||
Altman-Z | 8.15 |